Continuous Delivery in Oncology: Starton CEO at Boston Biotech Summit

PARAMUS, NJ – October 20, 2026 — The quest to develop novel oncology drugs often overshadows a parallel, equally vital pursuit: making the therapies we already have work better. This pragmatic approach to biotechnology is taking center stage as Starton Therapeutics prepares to present its strategic vision at the upcoming Longwood Healthcare Leaders Boston CEO meeting. On November 3, Chairman and Chief Executive Officer Pedro Lichtinger will join a panel of biopharmaceutical executives to discuss the intricacies of building global bioscience companies, offering a window into the strategic choices facing reformulatory drug delivery ventures today.

The invitation-only summit, scheduled for November 2-3 at the Mandarin Oriental in Boston, convenes a formidable cross-section of leaders from the pharmaceutical, biotechnology, academic, government, and investment communities. Known for its off-the-record panel discussions and fireside chats, the Longwood event serves as a critical nexus for drug development strategy, R&D collaboration, and high-level dealmaking. For a clinical-stage platform company navigating the complex transition from niche technology developer to global commercial player, securing a seat at this table is a highly calculated move.

Breathing New Life into Standard-of-Care

At the heart of the New Jersey-based firm's value proposition is a deceptively simple premise: the efficacy and tolerability of established cancer treatments can be radically improved by changing how they are delivered. The company's proprietary Temporal Controlled Pharmacology (TCP) platform is designed to maintain consistent therapeutic blood levels of standard-of-care therapies over a 24-hour period.

This continuous delivery mechanism directly addresses a pervasive challenge in oncology dosing. Traditional oral or intravenous administration often results in dramatic pharmacokinetic peaks and troughs. The high peak concentrations, or Cmax, are frequently responsible for severe, dose-limiting toxicities. Conversely, the sub-therapeutic troughs can compromise efficacy, providing a window for cancer cells to recover or develop resistance. By smoothing out these fluctuations, continuous delivery aims to extend patient exposure to effective doses while mitigating adverse side effects.

The clinical promise of this approach is most evident in the development of STAR-LLD, a continuous low-dose formulation of lenalidomide. An immunomodulatory imide drug (IMiD), lenalidomide has long been a cornerstone treatment for various blood cancers. However, its conventional oral administration is often hampered by significant hematologic toxicities.

Early clinical data suggests that continuous delivery could fundamentally alter this dynamic. In a Phase 1b clinical study involving six patients with relapsed or refractory multiple myeloma (RRMM), the subcutaneous infusion formulation (STAR-LLD-SC) demonstrated a striking 100% objective response rate, including one complete response and five partial responses. More notably, across up to 12 cycles of therapy, no patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2. This stark reduction in severe cytopenias points to a significantly improved tolerability profile compared to conventional oral lenalidomide.

The subcutaneous formulation is currently advancing through a Phase 2a randomized dose-escalation trial, comparing continuous infusion against the standard oral regimen in heavily treated multiple myeloma patients, with enrollment expected to conclude in the first half of 2027. Simultaneously, the company has partnered with Bend Bioscience to develop an oral controlled-release variant (STAR-LLD-OCR) targeting chronic lymphocytic leukemia and high-risk RRMM, leveraging advanced sustained-release tablet manufacturing.

Scaling From Niche Platform to Global Biopharma

The technological foundation is robust, but the transition from a clinical-stage innovator to a global biopharmaceutical entity requires a distinct strategic playbook. This is where Lichtinger's background becomes highly relevant to the upcoming Longwood panel discussion. With a career spanning over four decades, including pivotal roles as President of Global Primary Care and President of Europe at Pfizer Inc., Lichtinger brings a wealth of experience in scaling large pharmaceutical operations and navigating international commercialization.

The journey for his current enterprise has not been without its financial complexities. Like many clinical-stage biotechs, the firm has actively explored various avenues to secure the capital runway necessary to advance its pipeline. Following an initial attempt to enter the public markets via a merger with Healthwell Acquisition Corp. I, a Special Purpose Acquisition Company, in April 2023, the biotech subsequently filed an S-1 registration statement for a traditional initial public offering in December 2025. The proposed Nasdaq listing, targeting a $5.00 to $7.00 share price range, underscored a clear imperative to fund ongoing clinical development.

Against this backdrop of capital formation and clinical advancement, the Longwood Healthcare Leaders summit presents a timely platform. Industry analysts frequently point to these high-caliber, off-the-record forums as incubators for strategic alliances and institutional investment. Engaging directly with global pharma executives and top-tier healthcare investors allows clinical-stage leadership to pivot from purely scientific narratives to broader commercial strategies. The 'Building Global BioPharmas' panel will likely highlight the critical decision points these companies face: whether to pursue independent commercialization, seek out regional licensing agreements, or forge comprehensive global partnerships.

The Commercial Promise of Continuous Delivery

Beyond the immediate clinical benefits, the commercial implications of continuous delivery platforms are profound. For large pharmaceutical companies facing looming patent cliffs on blockbuster standard-of-care drugs, reformulation technologies offer a viable pathway to life cycle management. By demonstrating superior efficacy and tolerability profiles, continuous delivery variants can secure new intellectual property protections and carve out distinct market shares, effectively breathing new commercial life into proven active pharmaceutical ingredients.

The strategic vision extends beyond monotherapies. The clinical landscape of oncology is increasingly dominated by complex combination regimens and advanced modalities like CAR-T cell therapies and bispecific antibodies. The New Jersey biotech is actively positioning its continuous delivery technology within this evolving paradigm. The company has filed patent applications covering the delivery of its low-dose lenalidomide formulation in combination with CAR-T cell therapies and multi-specific antibodies.

The underlying rationale is compelling. By minimizing the baseline toxicity of the IMiD component, continuous delivery could enable patients to better tolerate the cumulative physiological burden of aggressive combination therapies. Early investigator-initiated trials are already exploring these synergistic applications in multiple myeloma and lymphoma. If successful, this approach could position the TCP platform not just as a standalone therapeutic improvement, but as an essential enabling technology for next-generation immunotherapies.

Navigating the Future of Oncology Investment

As the biotechnology sector continues to mature, the investment thesis is gradually shifting. While the pursuit of entirely novel mechanisms of action remains a high-risk, high-reward endeavor, there is a growing appreciation for the de-risked innovation offered by advanced delivery platforms. Utilizing approved active ingredients with established safety and efficacy profiles significantly truncates the early-stage discovery timeline and mitigates fundamental biological risk.

The challenge, therefore, lies in clinical execution and strategic positioning. The upcoming discussions at the Mandarin Oriental will undoubtedly reflect this nuanced reality. For executives like Lichtinger, the objective is to articulate how incremental technological improvements in drug delivery can translate into exponential gains in patient outcomes and commercial value.

The focus on continuous delivery highlights a broader industry trend toward patient-centric innovation. Maximizing the utility of existing pharmacopeia through sophisticated engineering represents a sustainable, highly impactful approach to disease management. As biopharmaceutical leaders convene in Boston to chart the future of the global life sciences industry, the integration of proprietary delivery technologies with standard-of-care therapies will remain a critical focal point for both medical advancement and strategic investment.